Exton, Pennsylvania, Nov. 07, 2023 (GLOBE NEWSWIRE) — Parkinson’s disease (PD) is the second-most prevalent neurodegenerative disorder following Alzheimer’s disease, affecting an estimated one million individuals in the United States1. With a significant absence of a definitive disease-modifying treatment capable of slowing its neurodegeneration, the current focus in PD care…Read More
US Neurologists Emphasize Tremendous Unmet Treatment Need in Parkinsons Disease According to Spherix Global Insights
